A Single Centre, Double Blind (Sponsor Open), Placebo Controlled, 3-Period Crossover, Ascending Dose Study in Japanese Healthy Elderly Male Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of Danirixin in the Fed State (Part1) and an Open Label, 2-way Crossover to Evaluate Food Effect on the Pharmacokinetics of Danirixin (Part2)
Phase of Trial: Phase I
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Danirixin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 14 Aug 2017 Status changed from recruiting to completed.
- 30 May 2017 Status changed from not yet recruiting to recruiting.
- 04 May 2017 New trial record